TIM-3 (CD366 or HAVCR2) is expressed on highly dysfunctional T cells, and TIM-3-associated drug resistance has been observed in HNSCC and non-small-cell lung cancer (NSCLC) (46, 47). This evidence concerns the gene HAVCR2 and head and neck squamous cell carcinoma.